Related Experiment Videos
Advances in chemotherapy for small cell lung cancer: single-agent activity of newer agents
1Northwestern University Medical School and Robert H. Lurie Comprehensive Cancer Center, Chicago, Illinois, USA.
Abstract:
Small cell lung cancer (SCLC) is a common neoplasm with an extremely poor prognosis. Patients with extensive-stage disease have a 5-year survival rate of 1% to 2%. Identification of new active chemotherapy agents is of great importance for the development of more effective treatment for SCLC. Several new drugs that have established a role in the management of non-SCLC in the past decade are also active in SCLC. The mean response rates in untreated versus previously treated patients for these newer drugs are: 26% versus 14% for vinorelbine, 27% versus 14% for gemcitabine, 45% versus 29% for paclitaxel, 22% versus 25% for docetaxel, 39% versus 19% for topotecan, and 50% versus 16% to 24% for irinotecan. A comparison of the response rates of those agents to more established drugs (e.g., cisplatin and etoposide) suggests that the newer drugs are equally or more active in previously treated patients with SCLC. This activity is even more impressive because initial therapy during the past decade has almost always included platinum and/or an epipodophyllotoxin in the regimen. Furthermore, a recent randomized trial showed that the combination of a newer agent (irinotecan) with cisplatin was superior to a standard etoposide and cisplatin regimen in patients with newly diagnosed extensive-stage SCLC. These data support further evaluation of the newer chemotherapeutic drugs, and especially the camptothecins (irinotecan and topotecan) and the taxanes (paclitaxel and docetaxel), in the initial treatment of SCLC.
Insights
Newer chemotherapy drugs show significant activity in treating small cell lung cancer (SCLC). Agents like irinotecan and paclitaxel offer improved response rates, especially in previously treated SCLC patients.
Area of Science:
- Medical Oncology
- Thoracic Oncology
- Cancer Chemotherapy
Background:
- Small cell lung cancer (SCLC) has a very poor prognosis, with a 5-year survival rate of 1-2% for extensive-stage disease.
- Developing novel chemotherapy agents is crucial for improving SCLC treatment efficacy.
Purpose of the Study:
- To evaluate the activity of newer chemotherapy agents in small cell lung cancer (SCLC).
- To compare the efficacy of novel drugs against established treatments for SCLC.
Main Methods:
- Review of response rates for newer chemotherapy agents (vinorelbine, gemcitabine, paclitaxel, docetaxel, topotecan, irinotecan) in untreated and previously treated SCLC patients.
- Comparison of newer agents' response rates with established drugs like cisplatin and etoposide.
- Analysis of a randomized trial comparing irinotecan plus cisplatin with etoposide plus cisplatin in newly diagnosed extensive-stage SCLC.
Main Results:
- Newer drugs demonstrated notable response rates in SCLC, with some exceeding established agents in previously treated patients.
- Camptothecins (irinotecan, topotecan) and taxanes (paclitaxel, docetaxel) showed particular promise.
- A combination of irinotecan and cisplatin proved superior to standard etoposide and cisplatin in newly diagnosed extensive-stage SCLC.
Conclusions:
- Newer chemotherapeutic drugs, particularly camptothecins and taxanes, are active in SCLC and warrant further investigation.
- These agents show potential for improving treatment outcomes in both newly diagnosed and previously treated SCLC patients.
- The findings support the integration of these newer agents into initial SCLC treatment regimens.